Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug could boost radiation for brain tumors in lung cancer patients

NCT ID NCT06238882

Disease control Sponsor: Instituto Nacional de Cancerologia de Mexico Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase III trial tests whether adding nitroglycerin patches to standard radiation therapy helps shrink brain tumors better than radiation alone in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). 74 participants will receive either radiation plus nitroglycerin or radiation alone. The study will measure tumor response, survival, quality of life, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nitroglycerin patch
What this could lead to
If it works, this could improve how well radiation shrinks brain tumors in people with a specific type of lung cancer, potentially extending life and preserving brain function.
What could go wrong
This is a small, early-stage trial (74 people) testing a repurposed drug. Nitroglycerin can cause headaches and low blood pressure, and the added benefit over radiation alone is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with advanced non-small cell lung cancer (which includes de novo stage IIIB-IV, according to the 8th edition AJCC, or recurrent disease), documented by histology and/or cytology. * Presence of brain metastases, candidates for treatment with holocranial radiation therapy. * Documented EGFR sensitivity mutation. * Disease measurable by criteria: The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM). * 18 years and up. * Functional status, by ECOG scale 0-2 * Life expectancy at least 12 weeks. * Not receive vasodilator treatment as calcium channel blockers. * Electrocardiogram * Neutrophil count 1.5 x 103/mm3, platelet count \>100 x (103/mm3). * Serum bilirubin should be 1.5 of the upper normal limit (ULN, upper normal limit). * AST and/or ALT 2 ULN (or 5 x ULN in patients with liver metastases). * Serum creatinine 1.5 (ULN), or creatinine clearance 60ml/min. * Ability to comply with study and follow-up procedures. * Informed written (signed) consent to participate in the study. * Have tumor tissue (paraffin blocks from diagnostic biopsy) obtained before systemic treatment Exclusion Criteria: * Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, ischemic heart disease, liver, kidney disease). * Patients with a history of allergy to glyceryl tinistate * Any other malignant pathology within the previous 5 years (except for cervical carcinoma in situ or basal-cell skin cancer, treated appropriately). * Pregnant and/or breastfeeding women. * Meningeal carcinomatosis corroborated by cytopathological study. Disposal Criteria: * Failure to follow protocol rules. * Loss of patient follow-up. * Patients who express their desire not to continue the study. * Patients with unacceptable toxicity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases EGFR gene mutation Non small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto Nacional de Cancerologia

    RECRUITING

    Mexico City, Mexico City, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.